Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers

Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers

Vesicular stomatitis virus (VSV) represents an attractive oncolytic virotherapy platform because of its potent tumor cell-killing and immune-stimulating properties; yet the clinical translation of VSV faces numerous challenges, such as inefficient systemic delivery and severe side effects such as ne...

Full description

Bibliographic Details
Main Authors: Michael Karl Melzer, Lisa Zeitlinger, Sabine Mall, Katja Steiger, Roland M. Schmid, Oliver Ebert, Angela Krackhardt, Jennifer Altomonte
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770518300366

Internet

http://www.sciencedirect.com/science/article/pii/S2372770518300366

Similar Items